Financials RUA Life Sciences plc

Equities

AOR

GB0033360586

Advanced Medical Equipment & Technology

Market Closed - London S.E. 09:05:10 09/05/2024 pm IST 5-day change 1st Jan Change
11.75 GBX 0.00% Intraday chart for RUA Life Sciences plc +5.62% +19.29%

Valuation

Fiscal Period: März 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 8.812 10.13 31.39 10.87 11.43 7.292 - -
Enterprise Value (EV) 1 8.812 8.158 25.34 8.213 9.941 3.633 4.346 4.092
P/E ratio - -12.4 x -17.3 x -5.26 x -5.7 x -2.71 x -7.83 x 16.8 x
Yield - - - - - - - -
Capitalization / Revenue 19 x 20.7 x 20.5 x 6.69 x 5.24 x 3.25 x 2.22 x 1.71 x
EV / Revenue 19 x 16.7 x 16.6 x 5.05 x 4.56 x 1.62 x 1.33 x 0.96 x
EV / EBITDA -21.7 x - -22 x -4.34 x - -2.05 x -5.14 x 6.02 x
EV / FCF - - - - - -2.02 x -5.43 x 5.85 x
FCF Yield - - - - - -49.6% -18.4% 17.1%
Price to Book - - - - - 1.05 x 1.21 x 1.11 x
Nbr of stocks (in thousands) 14,687 14,687 22,185 22,185 22,185 62,060 - -
Reference price 2 0.6000 0.6900 1.415 0.4900 0.5150 0.1175 0.1175 0.1175
Announcement Date 17/07/19 13/07/20 12/07/21 11/07/22 26/07/23 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 0.463 0.489 1.528 1.625 2.179 2.244 3.28 4.274
EBITDA 1 -0.407 - -1.151 -1.894 - -1.77 -0.845 0.68
EBIT 1 - -0.941 -1.551 -2.352 -2.306 -2.109 -1.162 0.33
Operating Margin - -192.43% -101.51% -144.74% -105.83% -93.96% -35.45% 7.72%
Earnings before Tax (EBT) 1 - -0.897 -1.594 -2.36 -2.332 -2.164 -1.282 0.29
Net income 1 - -0.816 -1.451 -2.067 - -1.835 -0.992 0.435
Net margin - -166.87% -94.96% -127.2% - -81.76% -30.25% 10.18%
EPS 2 - -0.0555 -0.0820 -0.0932 -0.0903 -0.0434 -0.0150 0.007000
Free Cash Flow 1 - - - - - -1.8 -0.8 0.7
FCF margin - - - - - -80.2% -24.39% 16.38%
FCF Conversion (EBITDA) - - - - - - - 102.94%
FCF Conversion (Net income) - - - - - - - 160.92%
Dividend per Share - - - - - - - -
Announcement Date 17/07/19 13/07/20 12/07/21 11/07/22 26/07/23 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2024 S1 2024 S2
Net sales - -
EBITDA - -
EBIT 1 - -0.81
Operating Margin - -
Earnings before Tax (EBT) - -
Net income 1 -1.01 -0.825
Net margin - -
EPS 2 -0.0455 -0.0204
Dividend per Share - -
Announcement Date 18/12/23 -
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 1.98 6.05 2.66 1.48 3.66 2.95 3.2
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - - - -1.8 -0.8 0.7
ROE (net income / shareholders' equity) - - - - - -28% -17.5% 7%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - - - - 0.1100 0.1000 0.1100
Cash Flow per Share - - - - - - - -
Capex 1 - - 0.62 0.9 0.45 0.25 0.07 0.1
Capex / Sales - - 40.58% 55.63% 20.61% 11.14% 1.98% 2.34%
Announcement Date 17/07/19 13/07/20 12/07/21 11/07/22 26/07/23 - - -
1GBP in Million2GBP
Estimates
  1. Stock Market
  2. Equities
  3. AOR Stock
  4. Financials RUA Life Sciences plc
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW